Hosted on MSN1mon
Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug(Bloomberg) -- Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based ...
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback